ompenaclid + FOLFIRI + bevacizumab

This combination therapy consists of **ompenaclid** (a novel investigational agent, details about its mechanism and developer are limited or not publicly disclosed), **FOLFIRI** (a chemotherapy regimen comprising folinic acid [leucovorin], fluorouracil [5-FU], and irinotecan), and **bevacizumab** (a humanized monoclonal antibody targeting vascular endothelial growth factor A [VEGF-A]). - FOLFIRI targets cancer cells by disrupting DNA synthesis and replication[1][3][5], with each component playing a distinct role: - *Fluorouracil (5-FU)*: an antimetabolite that incorporates into RNA and DNA, damaging nucleoside metabolism and irreversibly inhibiting thymidylate synthase[3]. - *Irinotecan*: inhibits topoisomerase I, blocking DNA replication[1][3]. - *Folinic acid*: enhances 5-FU effectiveness[1][5]. - Bevacizumab inhibits angiogenesis by blocking VEGF-A, preventing new blood vessel formation, thus starving tumors of nutrients and inhibiting metastasis[2][6][8]. - The inclusion of ompencaclid suggests potential molecularly targeted or novel mechanisms, but these are currently undefined in literature. This regimen is primarily used in the treatment of **metastatic colorectal cancer**, aiming to inhibit tumor growth, prolong survival, and manage advanced disease. The combination approach integrates cytotoxic, anti-angiogenic, and potentially targeted actions.

Other names

ompenaclid + FOLFIRI + bevacizumab